For needle-averse individuals, the convenience factor is substantial
Learn more: Cell by Cell Press Cell Press #neuroscience #neurology #durgdevelopment #clinicaltrials #diseasemodifyingtherapy #Alzheimer #Alzheimersdisease #dementia #cognitivedecline #tau #tauprotein #tauopathy #pathophysiology #neurodegeneration #neurodegenerativediseases #PET #PETimaging #neuroradiology #brainimaging #biomarkers #molecularimaging #tautherapy #ASO #anstisenseoligonucelotides #amyloid #immunization #ATN #immunotherapies #drugdiscovery #precisionmedicine #outcomes #outcomeresearch #trialdesign #adaptivedesign Figure: Lessons from anti-tau immunotherapies: Optimization of tau targeting and clinical trial design
:max_bytes(150000):strip_icc()/lamictal-withdrawal-symptoms-380259_v2-8c92ee1d1cf7493199fad1ba24c0da45.png)
In people, this hormone helps regulate blood sugar, slows digestion, and reduces appetite often leading to significant weight loss.In fact, according to a Guardian report, in the United States, a pilot study is testing GLP-1 drugs a category that includes Wegovy, Mounjaro, and Ozempic on cats.Given how widespread obesity has become among pets with some studies estimating up to 65% of dogs in the UK are overweight or obese the idea of using a drug to curb appetite and make pets slimmer has fueled interest among pet parents and biotech firms.In fact, a startup has reportedly begun early trials of a modified GLP-1 treatment for cats, under a project nicknamed MEOW-1, standing for ManagEment of Over Weight cats. According to a Guardian article, there are an estimated 54,500 diabetic cats in the UK, many of them already enduring a treatment consisting of twice-daily injections of insulin
doi: 10.1007/s00125-009-1643-x 37 LiuGMaHQiuLLiLCaoYMaJet al